0JDB.L - Invitae Corporation
LSE - LSE Prezzo differito. Valuta in USD.
Alla chiusura: 07:05PM BST
Il grafico dei titoli non è supportato dal tuo browser attuale
| Chiusura precedente | 1,0480 |
| Aperto | 0,0000 |
| Denaro | 0,0000 x 0 |
| Lettera | 0,0000 x 0 |
| Min-Max giorno | 0,0000 - 0,0000 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | 38.176 |
| Capitalizzazione | 960.050 |
| Beta (5 anni mensile) | 1,76 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,0560 |
| Prossima data utili | 07 ago 2023 - 11 ago 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireInvitae’s Real-World Ciitizen Data Utilized in Praxis Precision Medicines’ PRAX-222 IND Filing
First use of Ciitizen platform as source of real-world data in regulatory filingSAN FRANCISCO and BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Invitae (NYSE: NVTA) and Praxis Precision Medicines, Inc. (NASDAQ: PRAX), today announced that real-world clinical insights from Invitae’s Ciitizen platform were utilized as natural history data to support the submission of Praxis’ Investigational New Drug (IND) application for PRAX-222 for the treatment of pediatric patients with early-onset SCN2A developm